Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Early tumor shrinkage as a predictor of survival in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407.
Authors
Shun Tezuka
Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan;
Shun Tezuka , Masato Ozaka , Junji Furuse , Kohei Uemura , Yusuke Sano , Kohei Nakachi , Hiroshi Imaoka , Michiaki Unno , Hirofumi Shirakawa , Satoshi Shimizu , Naoya Kato , Yasushi Kojima , Keiji Sano , Makoto Ueno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 547)
DOI
10.1200/JCO.2023.41.4_suppl.547
Abstract #
547
Poster Bd #
C17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN.
First Author: Shun Tezuka
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka
Poster
2019 Gastrointestinal Cancers Symposium
FOLFIRINOX in pancreatic cancer patients age 75 years or older.
First Author: Jonathan Mizrahi
Poster
2016 Gastrointestinal Cancers Symposium
Early tumor shrinkage as a predictor of favorable outcomes in patients (pts) with advanced pancreatic cancer treated with FOLFIRINOX.
First Author: Yasuhiro Kaga